Kciuk, M.; Wanke, K.; Kruczkowska, W.; Marciniak, B.; Kontek, R.
Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. Molecules 2025, 30, 2686.
https://doi.org/10.3390/molecules30132686
AMA Style
Kciuk M, Wanke K, Kruczkowska W, Marciniak B, Kontek R.
Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. Molecules. 2025; 30(13):2686.
https://doi.org/10.3390/molecules30132686
Chicago/Turabian Style
Kciuk, Mateusz, Katarzyna Wanke, Weronika Kruczkowska, Beata Marciniak, and Renata Kontek.
2025. "Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review" Molecules 30, no. 13: 2686.
https://doi.org/10.3390/molecules30132686
APA Style
Kciuk, M., Wanke, K., Kruczkowska, W., Marciniak, B., & Kontek, R.
(2025). Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. Molecules, 30(13), 2686.
https://doi.org/10.3390/molecules30132686